MiR-200a with CDC7 as a direct target declines cell viability and promotes cell apoptosis in Wilm's tumor via Wnt/β-catenin signaling pathway

MiR-200a acts as a key role in tumor malignant progression. This work purposed to assess the function of miR-200a in Wilm's tumor. Based on bioinformatics analysis, the expression, prognostic value and related pathways of miR-200a and CDC7 (a potential downstream molecule of miR-200a) in Wilm's tumor were analyzed. qRT-PCR was conducted to confirm the miR-200a level in Wilm's tumor cells. The luciferase reporter assay was carried out to verify the binding of miR-200a to 3 '-UTR of CDC7. Then, the impacts of miR-200a and CDC7 on cell viability and apoptosis were measured using CCK-8 and flow cytometry assays. Also, western blot was applied to measure the expression of CDC7 as well as Wnt/beta-catenin signaling pathway-related proteins and apoptosis proteins. Herein, we revealed that miR-200a was lowly expressed in Wilm's tumor tissues and cells and the low miR-200a expression is closely bound up with death and poor outcomes. Moreover, miR-200a directly targeted and inhibited CDC7 in Wilm's tumor cells. Biological function experiments illustrated that overexpression of miR-200a reduced the viability and elevated the apoptosis of Wilm's tumor cells, while overexpression of CDC7 reversed the inhibitory impact of miR-200a on cell viability and the promoting impact of miR-200a on cell apoptosis. Besides, we revealed that miR-200a/CDC7 axis can decrease the expression of beta-Catenin, Cyclin D1 and C-Myc as well as the phosphorylation of GSK-3 beta, thus inhibiting the Wnt/beta-catenin signaling pathway. Furthermore, blocking the Wnt/beta-catenin signaling pathway caused an increase on cell apoptosis, while overexpression of CDC7 can reverse these impacts. Collectively, miR-200a/CDC7 axis involved in regulating the malignant phenotype of Wilm's tumor through Wnt/beta-catenin signaling pathway, which provides a theoretical basis for targeted molecular therapy of Wilm's tumor.

Automated summary

MiR-200a plays a crucial role in the malignant progression of tumors, with potential implications for Wilm's tumor. Lower expression of miR-200a in Wilm's tumor tissues and cells is associated with poorer outcomes and increased cell death. Additionally, miR-200a targets and inhibits CDC7 in Wilm's tumor cells, impacting cell viability and apoptosis. Further research into the miR-200a/CDC7 axis and its effects on the Wnt/beta-catenin signaling pathway provide a foundation for potential targeted molecular therapies for Wilm's tumor.